06.21.23
A polyphenol-rich grape and blueberry ingredient marketed by Activ’Inside as Memophenol was linked to a number of significant improvements in cognitive function scores in a group of 143 volunteers between the ages of 60 and 80. All participants self-reported difficiulties with cognition at baseline.
In total, participants were randomized to take either a placebo or a twice-daily dose of 150 mg of the supplement ingredient for a period of six months, and were evaluated with a cognitive test battery which included computer-based cognitive tasks, Behavior Rating Inventory of Executive Function (BRIEF-A), the cognitive failures questionnaire, and the CASP-19.
Compared to placebo, Memophenol supplementation was associated with greater improvements in the speed of information processing, visuospatial learning, and the BRIEF-A global score. However, there were no other significant between-group differences. The supplement was well-tolerated with no significant adverse events reported.
“The promising results from this trial suggest that six months of supplementation with Memophenol may improve aspects of cognitive function in adults with mild cognitive impairment,” the authors wrote. “Further research will be important to expand on the current findings and identify the potential mechanisms of action associated with the intake of this polyphenol-rich extract.”
Activ’Inside noted that this was the lowest dose used for this ingredient in which clinical efficacy for cognitive health outcomes was still achieved. The company noted that prior clinical evidence found that the ingredient was efficacious at dosages of 600 mg, which was linked to significant improvements in memory after chronic supplementation, and improvements in cognitive performance with acute usage. Following this study, a dosage of 300 mg of Memophenol was associated with significant improvements in cerebral blood flow and cognitive performance.
“These groundbreaking studies provide compelling evidence for the cognitive benefits of Memophenol at different dosages,” said David Gadout, chief innovations officer at Activ’Inside. “The results validate our hypothesis that Memophenol, even at a reduced dosage of 300 mg, can significantly enhance executive functions, speed of information processing, visuospatial episodic memory and learning, and reduce cognitive failures in older adults with MCI.”
In total, participants were randomized to take either a placebo or a twice-daily dose of 150 mg of the supplement ingredient for a period of six months, and were evaluated with a cognitive test battery which included computer-based cognitive tasks, Behavior Rating Inventory of Executive Function (BRIEF-A), the cognitive failures questionnaire, and the CASP-19.
Compared to placebo, Memophenol supplementation was associated with greater improvements in the speed of information processing, visuospatial learning, and the BRIEF-A global score. However, there were no other significant between-group differences. The supplement was well-tolerated with no significant adverse events reported.
“The promising results from this trial suggest that six months of supplementation with Memophenol may improve aspects of cognitive function in adults with mild cognitive impairment,” the authors wrote. “Further research will be important to expand on the current findings and identify the potential mechanisms of action associated with the intake of this polyphenol-rich extract.”
Activ’Inside noted that this was the lowest dose used for this ingredient in which clinical efficacy for cognitive health outcomes was still achieved. The company noted that prior clinical evidence found that the ingredient was efficacious at dosages of 600 mg, which was linked to significant improvements in memory after chronic supplementation, and improvements in cognitive performance with acute usage. Following this study, a dosage of 300 mg of Memophenol was associated with significant improvements in cerebral blood flow and cognitive performance.
“These groundbreaking studies provide compelling evidence for the cognitive benefits of Memophenol at different dosages,” said David Gadout, chief innovations officer at Activ’Inside. “The results validate our hypothesis that Memophenol, even at a reduced dosage of 300 mg, can significantly enhance executive functions, speed of information processing, visuospatial episodic memory and learning, and reduce cognitive failures in older adults with MCI.”
